SCHEMBL502850

SCHEMBL502850

C[C@H](OC[C@H](O)CO)c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
CYP1A2 P05177 2/20 0.40
LMNA P02545 2/20 0.40
AGTR1 P30556 1/20 0.40
TRPA1 O75762 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPK1 P28482 2/20 0.38
MITF O75030 1/20 0.38
ALDH1A1 P00352 1/20 0.38
XBP1 P17861 1/20 0.38
AOC3 Q16853 1/20 0.38
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 1/20 0.36
POLB P06746 1/20 0.36
SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502851 1.00 KDM4E (0.40) KDM4ECYP1A2LMNAAGTR1TRPA1
SCHEMBL503040 1.00 KDM4E (0.40) KDM4ECYP1A2LMNAAGTR1TRPA1
SCHEMBL574797 1.00 KDM4E (0.40) KDM4ECYP1A2LMNAAGTR1TRPA1
SCHEMBL16004867 0.82 CASR (0.47) KDM4ECYP1A2LMNAAGTR1TRPA1
SCHEMBL503052 0.81 TRPA1 (0.39) TRPA1AOC3HTTSLC6A2SLC6A4
SCHEMBL503051 0.81 TRPA1 (0.39) TRPA1AOC3HTTSLC6A2SLC6A4
SCHEMBL503338 0.81 TRPA1 (0.39) TRPA1AOC3HTTSLC6A2SLC6A4
SCHEMBL502893 0.76 ADRB2 (0.36) KDM4ELMNAMEN1KMT2AMAPK1
SCHEMBL502774 0.76 ADRB2 (0.36) KDM4ELMNAMEN1KMT2AMAPK1
SCHEMBL502775 0.76 ADRB2 (0.36) KDM4ELMNAMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132136-B2 Pharmaceutical combination HOFFMANN-LA ROCHE INC. (US) 2015-09-15 US disclosed
US-20130345201-A1 PHARMACEUTICAL COMBINATION HOFFMANN-LA ROCHE INC. (US) 2013-12-26 US disclosed
EP-2600853-A1 COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2013-06-12 EP disclosed
WO-2012016879-A1 COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-02-09 WO disclosed
US-20120028964-A1 PHARMACEUTICAL COMBINATION SEMINIS VEGETABLE SEEDS, INC. 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028964-A1 PHARMACEUTICAL COMBINATION TAAR1, TAAR5, MC2R KDM4E 4016/4885CYP1A2 225/4885LMNA 4479/4885
US-20130345201-A1 PHARMACEUTICAL COMBINATION TAAR1, TAAR5, MC2R KDM4E 4016/4885CYP1A2 225/4885LMNA 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.